FDA Approves ADALIMUMAB-BWWD — Cordavis Limited

Cordavis Limited announced the FDA approval of adalimumab-bwwd, a biosimilar of a major TNF-alpha inhibitor, allowing for the establishment of a new manufacturing platform designed to support an active global biosimilars strategy. This approval is anticipated to bolster Cordavis' competitive positioning in the biologics space, providing leverage for commercial partnerships and potential market expansion despite the patent expiration of the reference product.